T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as we...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Palecki, Amman Bhasin, Andrew Bernstein, Patrick J. Mille, William J. Tester, Wm. Kevin Kelly, Kevin K. Zarrabi
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Cancer Biology & Therapy
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/15384047.2024.2356820
Tags: Add Tag
No Tags, Be the first to tag this record!